Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00221546

Enrollment

Registered

2005-09-22

Start date

2007-09-30

Completion date

2008-09-30

Last updated

2011-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Detailed description

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

Interventions

DRUGGiving DHA-rich supplement

Giving DHA-rich supplement to patients.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

6 Years to No maximum

Healthy volunteers

Inclusion criteria

* Delta F 508 homozygote * Stable clinical situation

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Clinical evolution: weight, height, pulmonary function and infection frequency before the study start and during the 2 years of the study	before the study start and during the 2 years of the study

Secondary

Measure	Time frame
Evolution of the fatty acid profile	during the 2 years of the study
Oxidative stress status	during the 2 years of the study

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026